A Retrospective Analysis of the Growth Pattern in Patients with Salt-wasting 21-Hydroxylase Deficiency

Atsuko Kawano1, Hitoshi Kohno1, Kenichi Miyako1

  • 1Department of Endocrinology and Metabolism, Fukuoka Children's Hospital, Fukuoka, Japan.

Insights

Children with salt-wasting congenital adrenal hyperplasia (21-hydroxylase deficiency) experience growth suppression in infancy followed by inappropriate acceleration in childhood. Careful hydrocortisone dose adjustment is key for optimal adult height outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Genetics and Genetic Diseases
  • Growth and Development Disorders

Background:

  • Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is a group of inherited disorders.
  • The salt-wasting (SW) form of 21-OHD requires lifelong hormone replacement therapy.

Purpose of the Study:

  • To investigate the growth patterns in children diagnosed with SW 21-OHD.
  • To identify factors influencing adult height outcomes in this patient population.

Main Methods:

  • Retrospective analysis of medical records from 13 patients with SW 21-OHD diagnosed in infancy.
  • Evaluation of growth patterns, bone age, biochemical data, and hydrocortisone dosage throughout different growth stages.

Main Results:

  • Birth length was normal or above average, but height SD scores decreased below 0 during infancy.
  • Patients exhibited transient growth acceleration with peak velocity between 3-10 years of age.
  • Mean adult heights were 155.1 cm (females) and 158.1 cm (males).

Conclusions:

  • SW 21-OHD is associated with initial growth suppression followed by inappropriate childhood growth acceleration.
  • Optimizing hydrocortisone dosage, particularly reducing it in slow-growing infants and strictly managing it during childhood, may improve final adult height.